Development and validation of an UPLC-ESI-MS/MS method for quantification of duvelisib in plasma: application to pharmacokinetic study in rats

Duvelisib (DUV) is a new oral phosphoinositide-3-kinase (PI3K)-δ and PI3K-γ inhibitor. It is used for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This study describes the development and validation of a new highly sensitive and eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Darwish, Ibrahim A., Alzoman, Nourah Z., Almomen, Aliyah, Almehizia, Abdulrahman A., Attwa, Mohamed W., Darwish, Hany W., Sayed, Ahmed Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2023
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999367/
https://www.ncbi.nlm.nih.gov/pubmed/36909770
http://dx.doi.org/10.1039/d3ra00310h

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999367/
https://www.ncbi.nlm.nih.gov/pubmed/36909770
http://dx.doi.org/10.1039/d3ra00310h

Ejemplares similares